Cardiovascular Health Controlling Both HDL And LDL is Important Reducing the Risk of Coronary Heart Disease 3 Relative Risk In 4 Years 2 1 0 Increased Risk 25 55 85 HDL Cholesterol (mg/dl) 100 160 220 Increased Risk LDL Cholesterol (mg/dl) Framingham Study; Am J Cardiol 2000.
Torcetrapib CETP Inhibitor Tablet Target Indication and Phase 3 Timing Adjunctive Therapy with HMG-CoA Reductase Inhibitors or Ezetimibe for Treatment of Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial) or Mixed Dyslipidemia. Phase 3 Start: November 2007 Regulatory Status FDA Has Endorsed The Plan
Second-Generation CETP Inhibitors Two Agents Rapidly Moving Through Development CP-800,569: Novel Structural Class, Phase 1 Complete PF-3,185,043: Torcetrapib Analog in Phase 1 Neither Elevates Blood Pressure in Preclinical Models
CP-800,569 Phase 1 Multiple Dose HDL Pioneering NADDS (Nanoadsorbate Drug Delivery System) to Enable Phase 1 Clinical Studies FIH Single Dose Study Linear PK/Exposure from 30mg to 1100mg 14 Day Multiple Dose in Healthy Volunteers Safe & Well Tolerated, No BP Changes mean % change in HDL-C 160 140 120 100 80 60 40 20 0-20 % change in HDL-C 0 0.3 0.5 1 3 7 11 13 13.3 13.5 14 Days after Day 1 dosing 1100 mg 450 mg 150 mg 30 mg Placebo
CP-800,569 Phase 1 Multiple Dose LDL A7291003,1100 mg Multidose, Treated vs. Placebo Subjects: Changes in Plasma LDL-C (Friedewald Calculated) 30 Changes in plasma LDL-C (Friedewald calculated) 20 % change in LDL-C 10 0-10 -20-30 Treated, n = 8 Placebo, n = 2-40 -50-60 0 2 4 6 8 10 12 14 Time after first dose (days)
Driving New Science To Discover Valued Medicines Torcetrapib Maraviroc CP-690,550 Sutent, Axitinib Lyrica Chantix Compound Mechanism CETP Inhibition CCR-5 Inhibition Janus Kinase3 Inhibition Tyrosine Kinase Inhibition Alpha 2 Delta Blockade Nicotine Partial Agonism Atherosclerosis AIDS Rheumatoid Arthritis Cancer Disease Epilepsy, Neuropathic Pain Smoking Addiction
Changing How We Work The Challenge More Candidates Better Candidates Less Attrition in Early Development Enhanced Productivity Broaden Our Scope Through External Collaborations Sharper Focus on Major Medical and Commercial Opportunities
More and Better Candidates New Molecular Entities 2000 62 2007* 169 1990-2002 Early Candidate Attrition 2003-2005 35% 12% * Projected as of 1/07
Enhanced Productivity Discovery Research Creation of Centers of Emphasis for Key Technologies Non-Core Work Being Done in Low-Cost Environments Clinical Research Adaptive Clinical Designs Using Low-Cost, High-Quality Clinical Centers Infrastructure Improvement Reduction of Capital Budget by >60% Since 2002 Standardizations in it Resulting in 25% Cost Improvement with More Funding Allocated to New Application Design
Pharmaceutical Sciences Reorganization Doing More With Less Colleagues Annual Budget Pipeline New Molecular Entities Product Enhancements July 2002 3,800 >$1B 94 71 July 2006 2,668 $0.8B 153 77
Managing the Entire Life Cycle Therapeutic Areas Allergy and Respiratory Cardiovascular, Metabolic and Endocrine Dermatology Gastrointestinal / Liver Disease Genitourinary Inflammation Neurosciences Oncology Ophthalmology Pain Infectious Diseases
Therapeutic Area Strategy Unified View of the Future Patient and Environment Common Definition of Success Product Concepts Enabling Strategies Commitment to a Seamless Research, Development, and Commercialization Continuum One Customer-Centric Centric Strategic Vision Country WW Commercial Areas Research Development Commercial Patient and Shareholder Value First in Patient Submission Launch
What s s Different In Philosophy? A Call to the Scientists Around the World We Want to Collaborate With You We Want You to Bring Us Your Ideas and Suggestions We Want Your Advice
What s s Different In Philosophy? External Collaborations Bend Research TransTech
Pfizer External Research Network The Incubator Purpose: To Gain Rapid, Broader Access to Science Underlying Disease and to Enabling Technologies Site: Pfizer La Jolla Campus Will House 3-7 Unique Start-Ups Will Prove Infrastructure and Support Function: Small Teams Working to Provide Scientific Concepts Work on Problems Central to the PGRD Portfolio Once Concept is Proven, Continue as Either Pfizer- Associated or Independent Businesses
A Bright Future Real Momentum Aggressive Targets World-Class Science Will to Win
Today s s R&D Agenda Cardiovascular (Steve Ryder) Oncology (Declan Doogan) Neurosciences (Martin Mackay) Lunch Infectious Diseases (Ethan Weiner) Research Platforms (Martin Mackay) R&D Closing Remarks (John LaMattina) Business Transformation / External Sourcing (David Shedlarz / Ed Harrigan) Break Q & A Closing (Jeff Kindler)